Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amoxicillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 1/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 1/20 | 1.00 |
| ▸ | NR1I3 | Q14994 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.84 |
| ▸ | HPGD | P15428 | 3/20 | 0.84 |
| ▸ | POLB | P06746 | 2/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.84 |
| ▸ | TEK | Q02763 | 1/20 | 0.84 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.84 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amoxicillin SCHEMBL3427 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL13481266 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL18872879 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL13662733 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL13105238 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL24768939 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL226659 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL11378022 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL22380860 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL15387744 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1251990-A | Pharmaceutical formulation comprising amoxicillin and clavulanate | SMITHKLINE BEECHAM LAB (FR) | 2000-05-03 | — | — | CN | claimed |
| CN-118084926-A | Sp (sp)3Catalyst for primary amination of hydrocarbon bonds and process for preparing primary amine compounds | 四川大学华西第二医院 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023137519-A1 | CHIMERIC POLYPEPTIDES | Denteric Pty Ltd (AU) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023137522-A1 | CHIMERIC POLYPEPTIDES | Denteric Pty Ltd (AU) | 2023-07-27 | — | — | WO | disclosed |
| US-20210275559-A1 | HYGROMYCIN A COMPOUNDS AND METHODS OF TREATING SPIROCHETE DISEASES | NORTHEASTERN UNIVERSITY | 2021-09-09 | — | — | US | disclosed |
| EP-3840743-A1 | HYGROMYCIN A COMPOUNDS AND METHODS OF TREATING SPIROCHETE DISEASES | Northeastern University (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-106999463-B | Synergistic antimicrobial agents | SEPTEOS公司 | 2021-06-15 | — | — | CN | disclosed |
| US-10993935-B2 | Compositions and methods for treatment of lung infections | MARSHALL UNIVERSITY RESEARCH CORPORATION (US) | 2021-05-04 | — | — | US | disclosed |
| US-10758620-B2 | Potentiated antimicrobial agents | SEPTEOS (FR) | 2020-09-01 | — | — | US | disclosed |
| US-10668043-B2 | Potentiated antimicrobial agents | SEPTEOS (FR) | 2020-06-02 | — | — | US | disclosed |
| WO-2004071479-A1 | FILM FOAMING HYDROALCOHOLIC FOAM | CONNETICS AUSTRALIA PTY LTD (AU) | 2004-08-26 | — | — | WO | disclosed |
| EP-1311242-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | New River Pharmaceuticals, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002034237-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PHARMACEUTICALS, INC. (US) | 2002-05-02 | — | — | WO | disclosed |
| CN-1200672-A | pharmaceutical preparation | SMITHKLINE BEECHAM CORP (US) | 1998-12-02 | — | — | CN | disclosed |
| US-5827537-A | DRY BLENDING POTASSIUM CLAVULANATE AND HYDROPHOBIC WAXY MATERIAL FOR TRANSPORTATION WITHIN A CONTAINER | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-27 | — | — | US | disclosed |
| US-5824344-A | BLENDING OMOXACILLIN WITH GLYCERYL BEHENATE, COMPACTION, MILLING, SCREENING AND THERMAL INFUSION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-20 | — | — | US | disclosed |
| US-5690959-A | PREPARING CONTROLLED RELEASE SOLID DOSAGE FORMS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-25 | — | — | US | disclosed |
| US-5662941-A | ANTIBIOTICS | BOURBON PIERRE (FR) | 1997-09-02 | — | — | US | disclosed |
| US-5063064-A | Lithium fluoride | ATLANTIC PHARMACEUTICAL PRODUCTS LTD. (IE) | 1991-11-05 | — | — | US | disclosed |
| WO-1990001932-A1 | AMOXICILLIN MICROENCAPSULATED GRANULES | HIMEDICS, INC. (US) | 1990-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10758620-B2 | Potentiated antimicrobial agents | SLC11A2, FPR1, ATF1 | KDM4E 4794/4885LMNA 4561/4885RARB 3023/4885 |
| US-10668043-B2 | Potentiated antimicrobial agents | FPR1, ATF1, MPO | KDM4E 4684/4885LMNA 4086/4885RARB 4343/4885 |
| US-10993935-B2 | Compositions and methods for treatment of lung infections | CFTR, RIF1, FN1 | KDM4E 4848/4885LMNA 2186/4885RARB 1880/4885 |
| US-20210275559-A1 | HYGROMYCIN A COMPOUNDS AND METHODS OF TREATING SPIROCHETE DISEASES | TREH, GBA1, HSP90AB1 | KDM4E 3299/4885LMNA 604/4885RARB 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.